{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:37:09Z","timestamp":1782563829286,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.vaccine.2006.04.008","type":"journal-article","created":{"date-parts":[[2006,5,5]],"date-time":"2006-05-05T06:20:11Z","timestamp":1146810011000},"page":"5158-5168","source":"Crossref","is-referenced-by-count":117,"title":["Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines"],"prefix":"10.1016","volume":"24","author":[{"given":"William A.","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence M.","family":"Tumpey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airan D.A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald V.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill P.","family":"Adler-Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2006.04.008_bib1","unstructured":"CDC (Centers for Disease Control, Hong Kong). Isolation of avian influenza A (H5N1) viruses from humans. Morb Mortal Wkly Rep 1997;46:1204"},{"issue":"9182","key":"10.1016\/j.vaccine.2006.04.008_bib2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0140-6736(99)03311-5","article-title":"Human infection with influenza H9N2","volume":"354","author":"Peiris","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2006.04.008_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3201\/eid0505.990507","article-title":"The economic impact of pandemic influenza in the United States: priorities for intervention","volume":"5","author":"Meltzer","year":"1999","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2006.04.008_bib4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/nm757","article-title":"Lethal H5N1 influenza viruses escape host anti-viral cytokine responses","volume":"8","author":"Seo","year":"2002","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.vaccine.2006.04.008_bib5","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMp058068","article-title":"Preparing for the next pandemic","volume":"352","author":"Osterholm","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2006.04.008_bib6","unstructured":"Updated recommendations from the Advisory Committee on Immunization Practices in response to delays in supply of influenza vaccine for the 2000\u201301 season. MMWR Morb Mortal Wkly Rep 2000;49(39):888\u201392."},{"issue":"8","key":"10.1016\/j.vaccine.2006.04.008_bib7","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/JVI.62.8.2762-2772.1988","article-title":"Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions","volume":"62","author":"Zebedee","year":"1988","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.04.008_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/JVI.64.3.1375-1377.1990","article-title":"Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice","volume":"64","author":"Treanor","year":"1990","journal-title":"J Virol"},{"issue":"Pt 1","key":"10.1016\/j.vaccine.2006.04.008_bib9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1099\/0022-1317-74-1-143","article-title":"Antibody response to the M2 protein of influenza A virus expressed in insect cells","volume":"74","author":"Black","year":"1993","journal-title":"J Gen Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2006.04.008_bib10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/0264-410X(95)92777-Y","article-title":"Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein","volume":"13","author":"Slepushkin","year":"1995","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2006.04.008_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2006.04.008_bib12","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0264-410X(99)00005-5","article-title":"Modified M2 proteins produce heterotypic immunity against influenza A virus","volume":"17","author":"Frace","year":"1999","journal-title":"Vaccine"},{"issue":"23-24","key":"10.1016\/j.vaccine.2006.04.008_bib13","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/j.vaccine.2004.02.021","article-title":"Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys","volume":"22","author":"Fan","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.04.008_bib14","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/pro.5560011107","article-title":"A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41","volume":"1","author":"Fujii","year":"1992","journal-title":"Protein Sci"},{"key":"10.1016\/j.vaccine.2006.04.008_bib15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/pro.5560020813","article-title":"Defensins promote fusion and lysis of negatively charged membranes","volume":"2","author":"Fujii","year":"1993","journal-title":"Protein Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2006.04.008_bib16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0169-409X(99)00032-0","article-title":"To fuse or not to fuse: the effects of electrostatic interactions, hydrophobic forces, and structural amphiphilicity on protein-mediated membrane destabilization","volume":"38","author":"Fujii","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2006.04.008_bib17","unstructured":"Fujii G. Liposomal amphotericin B (AmBisome): realization of the drug delivery concept. In: Rosoff M, editor. Vesicles, vol. 12. New York: Marcel Dekker, Inc.; 1996. p. 491\u2013526."},{"key":"10.1016\/j.vaccine.2006.04.008_bib18","first-page":"493","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2006.04.008_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.20506\/rst.23.2.1493","article-title":"Microbial adaptation and change: avian influenza","volume":"23","author":"Webster","year":"2004","journal-title":"Rev Sci Tech"},{"issue":"9","key":"10.1016\/j.vaccine.2006.04.008_bib20","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.4049\/jimmunol.172.9.5598","article-title":"Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity","volume":"172","author":"Jegerlehner","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.04.008_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.virol.2005.06.006","article-title":"Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system","volume":"339","author":"Brett","year":"2005","journal-title":"Virolog"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2006.04.008_bib22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.3109\/10408418809104463","article-title":"Preparation and use of liposomes in the treatment of microbial infections","volume":"15","author":"Swenson","year":"1988","journal-title":"Crit Rev Microbiol"},{"issue":"22","key":"10.1016\/j.vaccine.2006.04.008_bib23","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0264-410X(99)00572-1","article-title":"Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration","volume":"18","author":"Baldridge","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.04.008_bib24","series-title":"Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein","author":"Wang","year":"2006"},{"issue":"8","key":"10.1016\/j.vaccine.2006.04.008_bib25","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3201\/eid0805.010476","article-title":"DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice","volume":"8","author":"Epstein","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"Part 8","key":"10.1016\/j.vaccine.2006.04.008_bib26","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1099\/0022-1317-83-8-1851","article-title":"Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus","volume":"83","author":"Heinen","year":"2002","journal-title":"J Gen Virol"},{"issue":"Part 6","key":"10.1016\/j.vaccine.2006.04.008_bib27","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1099\/0022-1317-70-6-1523","article-title":"Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins","volume":"70","author":"Jakeman","year":"1989","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.04.008_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0928-8244(03)00009-9","article-title":"N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication","volume":"35","author":"Liu","year":"2003","journal-title":"FEMS Immunol Med Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0600421X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0600421X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T12:59:57Z","timestamp":1586869197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0600421X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0264410X0600421X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.04.008","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}